



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dario NERI et al.

Examiner: Alana M. Harris

Serial No.: 09/194,356

Group Art Unit: 1642

Filed: September 2, 1999

Title: ANTIBODIES TO ED-B DOMAIN OF FIBRONECTIN, THEIR  
CONSTRUCTION AND USES

**NON-RESPONSIVE RESUBMISSION OF SLIDES**

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Being filed herewith is another copy of the five page powerpoint illustration mentioned in the first full paragraph on page 7 of the reply of October 5, 2006. Also filed is a copy of a PTO date-stamped filing receipt showing that the five slides indeed were submitted to the PTO on October 5, 2006.

The examiner may wish to pay particular attention to the second slide showing how oncofetal fibronectin comes in two different isoforms, one derived from ED-B and the other derived from a domain different from ED-B.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

  
Anthony J. Zelano, Reg. No. 27,969  
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: ELLIS-0003

Date: January 4, 2007

AJZ:hlw

K:\Ellis-3\Non-Responsive Resubmission.doc

SERIAL NO. 09/194,356

DOCKET NO. ELLIS-0003

FILED: September 2, 1999 APPLICANT(S) Dario NERI et al.

**THE PATENT AND TRADEMARK OFFICE STAMP HEREON ACKNOWLEDGES**

**RECEIPT OF THE FOLLOWING PAPERS:**

FILED BY CERTIFICATE OF MAILING ON:

FEES \$ 1200.00 Check No. 37961

MISSING PARTS RESPONSE W/DECL.

AMENDMENT

RESPONSE  ELECTION

NOTICE OF APPEAL

APPEAL BRIEF (TRIPPLICATE)

ASSIGNMENT

EXTENSION OF TIME 3 MO(S)

PRIORITY DOCUMENT(S)

VERIFIED STATEMENT(S) UNDER 37 C.F.R. 1.9 & 1.27

CONTINUATION PROSECUTION APPLICATION (CPA)

STATEMENT OF USE

ISSUE FEE

DECLARATION UNDER

INFORMATION DISCLOSURE

PTO 1449 W/ 4 REFS.

SHEETS OF DRAWINGS


COPY OF MISSING PARTS

RENEWAL APPLICATION

LETTER TO DRAFTSMAN

STATUS INQUIRY

APPLICATION DATA SHEET



**OTHER Declaration Under 37 CFR 1.132, Five slides**


Initials: AJZ/hlw

Date Filed: October 5, 2006




**“NORMAL” FIBRONECTIN:  
A SCHEMATIC REPRESENTATION**

- ❑ Twelve type I repeats (each repeat is homologous and is made by ~45 aminoacids)
- Two type II repeats (each repeat is homologous and is made by ~60 aminoacids)
- ❑ Fifteen type III repeats (each repeat is homologous and is made by ~90 aminoacids)




## “ONCOFETAL” FIBRONECTIN COMES IN TWO DIFFERENT ISOFORMS


1) B+ Fibronectin (when EDB is present)




2) Fibronectin with glycosylated III CS



IN THE "NORMAL" FIBRONECTIN MOLECULE  
THE ED-B DOMAIN IS NOT PRESENT



WHEN IN THE ONCOFETAL FIBRONECTIN (B<sup>+</sup> FIBRONECTIN TYPE)  
THE EDB DOMAIN IS PRESENT



THE EPITOPE ▲ FOR BC-1, CF-525 AND OAL-TFN-01 GET  
“UNMASKED” THUS BECOMING ACCESSIBLE FOR BINDING  
(Carnemolla *et al.*, 1992, *J Biol Chem*, 267, 24689-92)

HOWEVER THE ONLY ANTIBODIES DIRECTLY RECOGNIZING THE  
EDB ■ ARE THE ANTIBODIES DESCRIBED IN THIS PATENT  
SPECIFICATION

THE FDC6 ANTIBODY RECOGNIZES ONCOFETAL FIBRONECTIN WITH  
GLYCOSYLATED III CS BUT NOT THE ONCOFETAL B<sup>+</sup> FIBRONECTIN  
OR THE EDB

(Matsuura et al, J. Bio.Chem., Vol. 263, no. 7, 3314-3322, 1988)

